Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

Abstract

Advanced ovarian cancer is very responsive to first line platinum therapy, however almost invariably it relapses with a resistant disease. We have reported that patient derived ovarian xenografts (PDXs), independently from the degree of the initial response to cisplatin (DDP), show a significantly lower response to a second DDP cycle. We here report the… (More)
DOI: 10.1186/s12943-017-0662-3

Topics

5 Figures and Tables

Cite this paper

@inproceedings{Ricci2017CombinationOP, title={Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts}, author={Francesca Ricci and Federica Guffanti and Giovanna Damia and Massimo Broggini}, booktitle={Molecular Cancer}, year={2017} }